Luminescent sensor could enable high-throughput screening in presence of fluorescence
A bioluminescence resonance energy transfer sensor has been developed to report changes in intracellular Ca2+ concentrations during screening.
List view / Grid view
A bioluminescence resonance energy transfer sensor has been developed to report changes in intracellular Ca2+ concentrations during screening.
Using screening techniques, researchers have identified the compound called AN15368 which works as an antiparasitic against Chagas disease.
Trust in your results — Experience the benefits of iQue® advanced flow cytometry.
A new screening study has shown that three natural compounds present in foods like green tea may be candidates for drugs that combat the coronavirus.
In this episode, experts discuss how they use ELISA assays in their research as well as the specific benefits of this kind of immunoassay.
Are you using LC-MS in your drug development studies and looking to automate your sample prep workflow? Download our ebook to learn more.
7 September 2022 | By Sartorius
Watch this webinar to hear from Dr Yuansheng Yang as he introduces a CHO cell-based technology allowing simultaneous display and secretion of antibodies for accelerating the process of antibody development.
Application note: Quantifying T Cell response in 3D tumour spheroids using advanced flow cytometry workflows.
This publications review overviews advanced flow cytometry applications in infectious disease and immuno-oncology.
This guide highlights the four major stages of TPD, the challenges at each step and questions you should ask yourself.
Scientists have identified a molecule that can bind to a lethal subtype of the bacterial Shiga toxin, suppressing its deadly effects.
This whitepaper overviews how high throughput, multi-parametric analysis accelerates antibody discovery workflows.
Researchers from the US have identified several new small molecules that can induce mitophagy in leukaemia cells.
Researchers have identified a DNA-derived molecule that binds to and inhibits the function of CYP24 and shows promising antiproliferative activity.
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.